Antilumican

Manufactured by Santa Cruz Biotechnology

Antilumican is a laboratory reagent used for the detection and quantification of lumican, a proteoglycan found in the extracellular matrix. It is designed to assist researchers in studying the role of lumican in various biological processes.

Automatically generated - may contain errors

Lab products found in correlation

Anti erk1 2, by Santa Cruz Biotechnology (1 mentions) Anti β catenin, by Santa Cruz Biotechnology (1 mentions) Anti igf ir, by Santa Cruz Biotechnology (1 mentions) Pa5 37602, by Thermo Fisher Scientific (1 mentions) Ag1024, by Merck Group (1 mentions) Anti actin, by Merck Group (1 mentions) U0126, by Cell Signaling Technology (1 mentions) Keratanase 2, by Seikagaku (1 mentions)

2 protocols using antilumican

Antibody Validation for Extracellular Matrix Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used in this investigation: antiasporin (Thermo Fisher [PA5‐13553]; polyclonal rabbit IgG, diluted 1:1000 for western blotting and 1:100 for immunofluorescence); antilumican (Santa Cruz [sc‐33785]; polyclonal rabbit IgG, diluted 1:100 for western blotting); antimimecan/osteoglycin (Abcam [ab110558]; polyclonal rabbit IgG, diluted 1:1000 for western blotting); antimyomesin (gift from Elisabeth Ehler; mouse monoclonal IgG, clone B4 diluted 1:100 for immunofluorescence). In the case of asporin, for which band specificity was difficult to determine, we performed sequence alignment of the epitope and discovered homology to biglycan, which has predicted a molecular weight ≈5 kDa smaller than asporin; therefore, we believe the lower band visible on the membrane identifies biglycan. We ascribe the higher band to incomplete removal of glycosaminoglycans.

Brayson D., Holohan S., Bardswell S.C., Arno M., Lu H., Jensen H.K., Tran P.K., Barallobre‐Barreiro J., Mayr M., dos Remedios C.G., Tsang V.T., Frigiola A, & Kentish J.C. (2020). Right Ventricle Has Normal Myofilament Function But Shows Perturbations in the Expression of Extracellular Matrix Genes in Patients With Tetralogy of Fallot Undergoing Pulmonary Valve Replacement. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 9(16), e015342.

+ Open protocol

+ Expand

Investigating IGF-I and TGF-β2 Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human insulin-like growth factor I (IGF-I; 291-G1; 10 ng/ml) and transforming growth factor-β2 (TGF-β2; 302-B2-010; 10 ng/ml) were obtained from R&D Systems. A selective inhibitor of ERK1/2 (U0126; 10 μM; Cell Signaling Technology, Inc.) and allosteric inhibitor of IGF-IR (AG1024; 1 µM; Sigma-Aldrich; Merck KGaA) were used in the present study for 1 h. Primary antibodies from Santa Cruz Biotechnology, Inc. were used, and these included anti-lumican (sc166871; mouse monoclonal; 1/100 dilution for western blot analysis or 1/50 for immunofluorescence), anti-β-catenin (sc7963; mouse monoclonal; 1/300 dilution), anti-ERK1/2 (sc514302; mouse monoclonal; 1/200 dilution), anti-IGF-IR (sc81464; mouse monoclonal; 1/100 dilution), anti-pERK1/2 (sc136521; mouse monoclonal; 1/100 dilution), anti-Smad2 (sc6200; goat polyclonal; 1/200 dilution) and anti-pSmad2 (sc101801; rabbit polyclonal; 1/200 dilution). In addition, anti-actin (MAB1501; mouse monoclonal; 1/5,000 dilution; EMD Millipore), anti-p-IGF-IR (PA5-37602; polyclonal rabbit; 1/500 dilution; Thermo Fisher Scientific, Inc.), keratan sulfate (KS; 270427; mouse monoclonal; 1/1,000 dilution; Seikagaku Corporation) and keratanase II (100812; 0,005 µ/ml; Seikagaku Corporation) were utilized. Secondary-HRP antibodies anti-rabbit (AP182PR) and anti-mouse (AP192PM) were used at a 1/5,000 dilution and obtained from Millipore.

Papoutsidakis A., Giatagana E.M., Berdiaki A., Spyridaki I., Spandidos D.A., Tsatsakis A., Tzanakakis G.N, & Nikitovic D. (2020). Lumican mediates HTB94 chondrosarcoma cell growth via an IGF-IR/Erk1/2 axis. International Journal of Oncology, 57(3), 791-803.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!